Colorectal Cancer: Isofol’s Modufolin Could Change Mainstay Therapy

Decades-long academic and pharma research to improve on the benefits of the 5-fluorouracil and Leucovorin combination in colorectal cancer has reached a crucial point, with a multinational Phase III pivotal trial of Isofol’s Modufolin being cleared by regulators but funding is still needed.

Gothenberg, Sweden-based biotech Isofol Medical AB expects to start a pivotal Phase III study at the end of 2017 with its single asset, Modufolin, potentially a more effective product to combine with 5-fluorouracil (5-FU) than conventional Leucovorin (folinic acid).

The company is currently working on raising new funds for the study that could include an initial public offering. Over...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

Nuvation Set For First Launch With Ibtrozi In Lung Cancer

 

The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.